177 related articles for article (PubMed ID: 37290104)
41. Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
Straub MM; Podoll MB; David SN; Wiesner GL; Desouki MM
Ann Diagn Pathol; 2018 Oct; 36():28-30. PubMed ID: 30055521
[TBL] [Abstract][Full Text] [Related]
42. Risk reducing surgery with peritoneal staging in BRCA1-2 mutation carriers. A prospective study.
Marchetti C; Arcieri M; Vertechy L; Ergasti R; Russo G; Zannoni GF; Minucci A; Ercoli A; Scambia G; Fagotti A
Eur J Surg Oncol; 2022 Dec; 48(12):2539-2544. PubMed ID: 35871032
[TBL] [Abstract][Full Text] [Related]
43. Theory-based behavior change intervention to increase uptake of risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 pathogenic variant: The PREVENT randomized controlled trial.
Metcalfe KA; Pal T; Narod SA; Armel S; Shickh S; Buckley K; Walters ST; Brennenstuhl S; Kinney AY
Cancer Med; 2023 Sep; 12(17):18246-18257. PubMed ID: 37602539
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study.
Cortesi L; De Matteis E; Toss A; Marchi I; Medici V; Contu G; Xholli A; Grandi G; Cagnacci A; Federico M
Oncology; 2017; 93(6):377-386. PubMed ID: 28848147
[TBL] [Abstract][Full Text] [Related]
45. Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.
Shu CA; Pike MC; Jotwani AR; Friebel TM; Soslow RA; Levine DA; Nathanson KL; Konner JA; Arnold AG; Bogomolniy F; Dao F; Olvera N; Bancroft EK; Goldfrank DJ; Stadler ZK; Robson ME; Brown CL; Leitao MM; Abu-Rustum NR; Aghajanian CA; Blum JL; Neuhausen SL; Garber JE; Daly MB; Isaacs C; Eeles RA; Ganz PA; Barakat RR; Offit K; Domchek SM; Rebbeck TR; Kauff ND
JAMA Oncol; 2016 Nov; 2(11):1434-1440. PubMed ID: 27367496
[TBL] [Abstract][Full Text] [Related]
46. Clinical background and outcomes of risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancers in Japan.
Nomura H; Sekine M; Yokoyama S; Arai M; Enomoto T; Takeshima N; Nakamura S
Int J Clin Oncol; 2019 Sep; 24(9):1105-1110. PubMed ID: 31055694
[TBL] [Abstract][Full Text] [Related]
47. Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study.
Pla-Juher H; Pardo M; Izquierdo ÀJ; Darder E; Carbó A; Munté E; Torres-Esquius S; Balmaña J; Lázaro C; Brunet JM; Barretina-Ginesta MP
Clin Transl Oncol; 2024 Apr; 26(4):1033-1037. PubMed ID: 37682500
[TBL] [Abstract][Full Text] [Related]
48. Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy.
Teixeira N; Mourits MJ; Oosterwijk JC; Fakkert IE; Absalom AR; Bakker SJL; van der Meer P; de Bock GH
Fam Cancer; 2019 Jan; 18(1):19-27. PubMed ID: 29881922
[TBL] [Abstract][Full Text] [Related]
49. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.
van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP
Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902
[TBL] [Abstract][Full Text] [Related]
50. Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy.
Cohen JV; Chiel L; Boghossian L; Jones M; Stopfer JE; Powers J; Rebbeck TR; Nathanson KL; Domchek SM
Fam Cancer; 2012 Mar; 11(1):69-75. PubMed ID: 21898151
[TBL] [Abstract][Full Text] [Related]
51. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.
Marchetti C; De Felice F; Boccia S; Sassu C; Di Donato V; Perniola G; Palaia I; Monti M; Muzii L; Tombolini V; Benedetti Panici P
Crit Rev Oncol Hematol; 2018 Dec; 132():111-115. PubMed ID: 30447915
[TBL] [Abstract][Full Text] [Related]
52. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
[TBL] [Abstract][Full Text] [Related]
53. No signs of subclinical atherosclerosis after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers.
van Bommel MHD; de Jong MA; Steenbeek MP; Bots ML; van Westerop LLM; Hopman MTE; Hoogerbrugge N; de Hullu JA; Maas AHEM
J Cardiol; 2021 Jun; 77(6):570-575. PubMed ID: 33229237
[TBL] [Abstract][Full Text] [Related]
54. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
[TBL] [Abstract][Full Text] [Related]
55. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.
Fakkert IE; Mourits MJ; Jansen L; van der Kolk DM; Meijer K; Oosterwijk JC; van der Vegt B; Greuter MJ; de Bock GH
Cancer Prev Res (Phila); 2012 Nov; 5(11):1291-7. PubMed ID: 23009828
[TBL] [Abstract][Full Text] [Related]
56. The Role of Routine Peritoneal and Omental Biopsies at Risk-Reducing Salpingo-Oophorectomy.
Miller H; Pipkin LS; Tung C; Hall TR; Masand RP; Anderson ML
J Minim Invasive Gynecol; 2017; 24(5):772-776. PubMed ID: 28285055
[TBL] [Abstract][Full Text] [Related]
57. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
Kauff ND; Barakat RR
J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
[TBL] [Abstract][Full Text] [Related]
58. Differences in age at diagnosis of ovarian cancer for each
Sekine M; Enomoto T; Arai M; Den H; Nomura H; Ikeuchi T; Nakamura S;
J Gynecol Oncol; 2022 Jul; 33(4):e46. PubMed ID: 35557031
[TBL] [Abstract][Full Text] [Related]
59. Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers.
Gaba F; Manchanda R
Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():46-65. PubMed ID: 32192936
[TBL] [Abstract][Full Text] [Related]
60. Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.
Mai PL; Piedmonte M; Han PK; Moser RP; Walker JL; Rodriguez G; Boggess J; Rutherford TJ; Zivanovic O; Cohn DE; Thigpen JT; Wenham RM; Friedlander ML; Hamilton CA; Bakkum-Gamez J; Olawaiye AB; Hensley ML; Greene MH; Huang HQ; Wenzel L
Gynecol Oncol; 2017 Apr; 145(1):122-129. PubMed ID: 28190649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
